Abstract
CTLA4 blockers have limited activity in patients with chemorefractory lung cancer. Recent clinical data demonstrate that radiation therapy combined with CTLA4 blockers enables disease control in a sizeable fraction of these patients, correlating with increased circulating levels of type I interferon and dynamic changes in the peripheral T cell repertoire.
| Original language | English |
|---|---|
| Article number | e1606624 |
| Journal | Oncoimmunology |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2019 |
| Externally published | Yes |
Keywords
- CGAS
- ipilimumab
- non-small cell lung carcinoma
- STING
- TREX1
- type I interferon